Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings over 20 years of neuroscience-focused medical affairs leadership, having held key positions at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. His expertise is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
The company is currently developing two lead candidates: HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration; and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs aimed at addressing large unmet needs in mental health conditions such as depression and anxiety.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is committed to developing synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company’s proprietary NSAs aim to provide durable improvements in mental health and improve the treatment landscape. The appointment of Dr. Kramer underscores Helus Pharma’s focus on advancing its clinical programs and building robust medical affairs capabilities to support the development and potential commercialization of its pipeline.
For more details on the appointment, the full press release can be viewed at https://ibn.fm/FdEXH. Company updates and further information about Helus Pharma are available at www.helus.com or by following the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma™ is a trademark of Cybin Corp.
This announcement was disseminated by TinyGems, a specialized communications platform focusing on innovative small-cap and mid-cap companies. TinyGems is one of over 75 brands within the Dynamic Brand Portfolio @IBN that delivers wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit https://www.TinyGems.com.
